Softchoice’s shares surged Tuesday after the Canadian software company agreed to be bought by World Wide Technology in a deal implying an enterprise value of 1.8 billion Canadian dollars ($1.25 billion).
SiriusPoint shares rose Tuesday after it said it would repurchase $733 million worth of its shares from CM Bermuda.
SYDNEY — Australian house prices recorded their first monthly decline in almost two years in December, but relief for the market appears close amid growing speculation that the Reserve Bank of Australia will start cutting interest rates from February.
The FDA is elevating three sets of respiratory hardware recalls from Smiths Medical, covering portable ventilators and tracheostomy tubes that enter the airway through the neck. The agency categorized each of them as Class I recalls, its most serious type.
To help clinical trial sponsors who are planning global cancer studies best position themselves for FDA approval, the agency has released draft guidance for conducting multiregional clinical trials in oncology. The draft includes considerations for selecting clinical trial sites, analyzing data and incorporating regional information about the disease and available treatments.
Biohaven has linked troriluzole to a significant slowing of progression in an ultra-rare disease, setting the biotech up to take another shot at winning approval with an asset that the FDA refused to review last year.
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival (OS) in a phase 3 trial. The latest miss happened in breast cancer, a setting in which Gilead Sciences’ rival Trodelvy significantly improved OS in a prior late-phase study.
The stroke devicemaker Route 92 Medical has raised $50 million in funds, as it looks to expand the worldwide commercial reach of its clot-busting hardware.
Black Diamond Therapeutics and Ideaya Biosciences are mulling over registrational trials for their lead assets after receiving encouraging phase 2 data in lung and eye cancers, respectively.
After a series of trials and tribulations, Ventyx Biosciences has received a $27 million boost from Sanofi, money that is expected to extend the biotech’s cash runway into the second half of 2026.
Jasper dials up dose after complete responses come and go quickly in hives trial
Novartis channels Gargamel, terminating midphase SMURF1 trial
Transgene’s viral cancer vaccine flunks midphase test—but subgroup signal spurs ongoing analysis
Lilly picks UK for first European Gateway Lab as part of $364M investment plan
Capricor cell therapy improves cardiac and upper limb function in phase 2 Duchenne muscular dystrophy victory lap
After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen
Bruker spools up spatial biology division from NanoString, Canopy assets
Turnstone lays off 60% of staff, shakes up C-suite to keep cancer cell therapy on track
Deep learning AI model scans ‘dark matter’ of genomic data to find 70,000 never-before-seen RNA viruses
Novo Holdings-backed Booster takes off with protein degraders aimed at neurodegeneration
